Checkmate Pharmaceuticals LLC

https://www.checkmatepharma.com

Checkmate Pharmaceuticals is a research and development company pursuing a novel approach to specifically activating the innate arm of the immune system to recognize and ultimately destroy tumor cells. The company is leveraging their expertise and the vast body of knowledge in the field of CpG oligonucleotides and is validating an approach that will combine the ability of CpG DNA to activate an anti-tumor T cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. Checkmate’s founder and CEO, Dr. Art Krieg, discovered CpG DNA in 1994. Since then CpG DNAs have been administered to thousands of patients showing potent immune activation and a good safety profile. Checkmate is a privately held company headquartered in Cambridge, MA. *

	Start	2015-08-12 existent
	End	2020-08-03 renamed before
	Group	Regeneron (Group)
	Today	Checkmate Pharmaceuticals Inc. (Nasdaq: CMPI)
	Successor	Checkmate Pharmaceuticals Inc. (Nasdaq: CMPI)
	Industry	CMP-001 (formerly CYT003) (Checkmate Pharma / Kuros / Cytos)
	Industry 2	VLP technology (virus-like particle technology)
	Person	Krieg, Arthur (Art) (Checkmate Pharmaceuticals 201508 CEO + Founder)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	1 Broadway 14th Floor
	City	02142 Cambridge, MA
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10